Oculis (NASDAQ:OCS - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $39.00 price objective on the stock. HC Wainwright's price objective suggests a potential upside of 411.14% from the company's current price.
A number of other research analysts also recently commented on OCS. Guggenheim dropped their price objective on shares of Oculis to $40.00 and set a "buy" rating for the company in a research note on Wednesday, November 4th. Weiss Ratings reissued a "sell (d-)" rating on shares of Oculis in a research report on Thursday, October 15th. JPMorgan Chase & Co. decreased their target price on shares of Oculis from $23.00 to $20.00 and set an "overweight" rating on the stock in a research report on Friday, August 14th. Finally, Wall Street Zen upgraded shares of Oculis from a "strong sell" rating to a "sell" rating in a report on Saturday, August 8th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Oculis currently has a consensus rating of "Moderate Buy" and an average price target of $38.57.
Read Our Latest Report on OCS
Oculis Stock Performance
Oculis stock opened at $7.63 on Tuesday. The firm has a market capitalization of $442.39 million, a P/E ratio of -4.46 and a beta of 0.67. The stock has a fifty day moving average price of $8.65 and a 200 day moving average price of $17.77. Oculis has a 52 week low of $6.78 and a 52 week high of $34.47. The company has a current ratio of 10.41, a quick ratio of 10.41 and a debt-to-equity ratio of 0.01.
Oculis (NASDAQ:OCS - Get Free Report) last released its earnings results on Tuesday, November 3rd. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.10. Oculis had a negative return on equity of 39.24% and a negative net margin of 8,613.92%. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.26 million. Equities research analysts anticipate that Oculis will post -1.83 earnings per share for the current year.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in the company. Braidwell LP acquired a new stake in Oculis during the second quarter worth about $11,570,000. Bank of America Corp DE raised its holdings in shares of Oculis by 9.1% in the 1st quarter. Bank of America Corp DE now owns 69,764 shares of the company's stock worth $1,855,000 after purchasing an additional 5,813 shares during the period. Himension Capital Singapore PTE. LTD. purchased a new position in shares of Oculis in the 1st quarter worth about $503,000. Aquatic Capital Management LLC purchased a new position in shares of Oculis in the 3rd quarter worth about $134,000. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Oculis by 103.9% in the 3rd quarter. Goldman Sachs Group Inc. now owns 141,688 shares of the company's stock valued at $1,323,000 after purchasing an additional 72,186 shares in the last quarter. 22.30% of the stock is owned by hedge funds and other institutional investors.
About Oculis
(
Get Free Report)
Oculis is a clinical-stage biopharmaceutical company developing treatments for eye diseases. Founded in 2017, the company is headquartered in Switzerland and conducts research and development across multiple locations. Its investigational pipeline includes therapies for conditions such as diabetic macular edema, dry eye disease and optic neuritis. The programs use approaches including topical eye-drop delivery and neuroprotection, with candidates at different stages of clinical development. Oculis focuses on developing treatments for patients worldwide.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oculis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.
While Oculis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.